Pre-made Denosumab benchmark antibody ( Whole mAb, anti-TNFSF11/ODF therapeutic antibody, Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Denosumab biosimilar, Whole mAb, Anti-TNFSF11/ODF Antibody: Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
| Products Name (INN Index) | Pre-Made Denosumab biosimilar, Whole mAb, Anti-TNFSF11/ODF Antibody: Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 therapeutic antibody |
|---|---|
| INN Name | Denosumab |
| Target | TNFSF11 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | Amgen,Daiichi Sankyo Company,European Thoracic Oncology Platform,GlaxoSmithKline,Jules Bordet Institute,Melbourne Health,University Health Network |
| Conditions Approved | Bone cancer,Bone disorders,Bone metastases,Corticosteroid-induced osteoporosis,Male osteoporosis,Malignant hypercalcaemia,Osteoporosis,Postmenopausal osteoporosis,Rheumatoid arthritis |
| Conditions Active | Breast cancer,Non-small cell lung cancer,Osteogenesis imperfecta,Malignant melanoma |
| Conditions Discontinued | Multiple myeloma |
| Development Tech | Abgenix XenoMouse |
| Previous Name | NA |
| Gm Offical Target Name | TNFSF11/ODF |
| Package |
